What happened
QuadMedicine disclosed a supply contract with Hanlim Pharmaceutical Co., Ltd., worth US$4.02M, about 56.1% of its recent annual revenue, running through Mar 2027.
For context, this single contract equals about 56.1% of the company's most recent annual revenue.
| Counterparty | Hanlim Pharmaceutical Co., Ltd. |
|---|---|
| Contract value | US$4.02M |
| vs. recent revenue | 56.1% |
| Through | Mar 2027 (from May 2026) |
| Filed | 2026-05-15, Supply contract signed |
| Source | DART rcept 20260515901130 → open original filing |
Source: DART. Information only, not investment advice.